Login to Your Account

Vertex Targets Kalydeco as Incivek Sales Continue Swoon

By Marie Powers
Staff Writer

Wednesday, January 30, 2013
After Tuesday's market close, Vertex Pharmaceuticals Inc. reported 2012 revenues of $1.53 billion, including net product revenues of $1.16 billion from Incivek (telaprevir) and $171.6 million from Kalydeco (ivacaftor), launched in the U.S. in February 2012.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription